Deutsche Pharma Holding GmbH
Deutsche Pharma Holding GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany (DE) and operates extensively across Europe and beyond. Founded in the early 2000s, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, focusing on prescription medications and over-the-counter products. With a commitment to quality and efficacy, Deutsche Pharma offers a diverse portfolio that includes specialty pharmaceuticals and generics, catering to various therapeutic areas. The company is recognised for its rigorous research and development processes, ensuring that its products meet the highest standards of safety and effectiveness. Deutsche Pharma Holding GmbH has achieved significant milestones, positioning itself as a trusted name in the market, known for its dedication to improving patient outcomes and advancing healthcare solutions.
DitchCarbon Score
How does Deutsche Pharma Holding GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Deutsche Pharma Holding GmbH's score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Deutsche Pharma Holding GmbH's reported carbon emissions
In 2023, Deutsche Pharma Holding GmbH reported total carbon emissions of approximately 643,060 kg CO2e. This figure includes 72,540 kg CO2e from Scope 1 emissions, 23,960 kg CO2e from Scope 2 emissions, and a significant 543,560 kg CO2e from Scope 3 emissions, which encompasses areas such as business travel (122,230 kg CO2e) and purchased goods and services (183,480 kg CO2e). Comparatively, in 2022, the company emitted about 276,780 kg CO2e, with Scope 1 emissions at 63,950 kg CO2e, Scope 2 at 21,120 kg CO2e, and Scope 3 at 162,710 kg CO2e. This indicates an increase in total emissions year-on-year, particularly in Scope 3, which is often the most challenging to manage. Despite the lack of specific reduction targets or initiatives disclosed, Deutsche Pharma Holding GmbH is actively monitoring its emissions across all scopes. The company has not yet committed to any science-based targets or climate pledges, which are essential for aligning with global climate goals. As the pharmaceutical industry faces increasing scrutiny regarding sustainability, Deutsche Pharma Holding GmbH's future commitments will be crucial in addressing its carbon footprint and enhancing its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 69,400 | 00,000 | 00,000 |
| Scope 2 | 20,490 | 00,000 | 00,000 |
| Scope 3 | 172,010 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Deutsche Pharma Holding GmbH is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
